Arbutus terminates RSV side deal with Genevant, discloses CEO and CFO Moderna bonuses
The same 8-K disclosing new Pfizer/BioNTech suits and the $230M buyback also reveals a terminated RSV agreement and litigation bonuses for Arbutus executives.
Arbutus Biopharma Corporation disclosed in a July 16, 2026 Form 8-K that it terminated a March 2025 side agreement with Genevant Sciences GmbH covering potential damages from Moderna's respiratory syncytial virus vaccine mRESVIA. Under that original agreement, Arbutus was entitled to any damages or settlement proceeds from Moderna litigation specifically allocated to infringing acts related to mRESVIA, with the companies agreeing to negotiate an allocation in good faith if none was specified.1 A March 2026 settlement agreement between Arbutus, Genevant, Genevant's parent, and Moderna resolved all pending global patent litigation but did not specifically allocate any proceeds to mRESVIA.1 As a result, on July 15, 2026, Arbutus and Genevant signed a termination agreement ending the RSV side deal, with Genevant agreeing to pay Arbutus a $1.0 million termination fee within ten business days.1
The filing also detailed new executive compensation tied to the Moderna settlement. The Arbutus board approved a bonus agreement for President and CEO Lindsay Androski providing 1.5% of the company's share of the noncontingent Moderna settlement payment, 2.0% of any future contingent Moderna-related proceeds, and 2.5% of any proceeds from the Pfizer/BioNTech litigation.1 The first bonus will be paid by the end of July 2026, while the other bonuses depend on specified conditions including continued employment.1
CFO Tuan Nguyen also received a discretionary bonus equal to 0.25% of all proceeds tied to the noncontingent settlement payment, including any dividend from Genevant's parent, with a possible future bonus of 0.25% of remaining Moderna-related proceeds at the board's discretion.1 Nguyen's initial bonus payment will be made by the end of July 2026, based on the July 8 settlement receipt, with a second installment following any dividend from Genevant's parent, contingent on continued employment.1
These disclosures accompany the same filing's previously reported news of new Pfizer/BioNTech patent suits, the $178 million Moderna payment, and the planned up to $230 million share buyback, all announced together on July 16, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.